Cervomed announces oral presentation at 19th international conference on alzheimer's and parkinson's diseases and related neurologic disorders (ap/pd™)

Boston, march 25, 2025 (globe newswire) -- cervomed inc. (nasdaq: crvo), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th international conference on alzheimer's and parkinson's diseases and related neurologic disorders (ap/pd™), being held on april 1-5, 2025 in in vienna, austria. the company will be presenting detailed analyses from the extension phase of the rewind-lb phase 2b study of neflamapimod in dementia with lewy bodies (dlb).
CRVO Ratings Summary
CRVO Quant Ranking